| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 75 | 2023 | 5319 | 5.560 |
Why?
|
| Lung Neoplasms | 96 | 2023 | 11538 | 4.840 |
Why?
|
| Carcinoma, Squamous Cell | 53 | 2021 | 5437 | 3.470 |
Why?
|
| Mouth Neoplasms | 23 | 2023 | 713 | 2.260 |
Why?
|
| ErbB Receptors | 23 | 2023 | 2295 | 1.900 |
Why?
|
| Precancerous Conditions | 22 | 2018 | 1058 | 1.860 |
Why?
|
| Head and Neck Neoplasms | 36 | 2023 | 3976 | 1.780 |
Why?
|
| Molecular Targeted Therapy | 15 | 2020 | 2330 | 1.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 52 | 2023 | 15862 | 1.450 |
Why?
|
| Protein Kinase Inhibitors | 17 | 2023 | 4757 | 1.430 |
Why?
|
| Leukoplakia, Oral | 11 | 2023 | 70 | 1.340 |
Why?
|
| Antineoplastic Agents | 33 | 2020 | 14289 | 1.320 |
Why?
|
| Anticarcinogenic Agents | 10 | 2016 | 362 | 1.270 |
Why?
|
| Biomarkers, Tumor | 31 | 2023 | 10331 | 1.090 |
Why?
|
| Acrylamides | 8 | 2020 | 53 | 1.030 |
Why?
|
| Precision Medicine | 9 | 2020 | 1154 | 1.020 |
Why?
|
| Drug Resistance, Neoplasm | 13 | 2018 | 5178 | 1.010 |
Why?
|
| Pemetrexed | 8 | 2020 | 102 | 0.920 |
Why?
|
| Carboplatin | 17 | 2019 | 823 | 0.900 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2018 | 665 | 0.880 |
Why?
|
| Aniline Compounds | 7 | 2020 | 177 | 0.830 |
Why?
|
| Mutation | 29 | 2023 | 15179 | 0.830 |
Why?
|
| Isotretinoin | 11 | 2011 | 158 | 0.820 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2018 | 447 | 0.800 |
Why?
|
| Clinical Trials as Topic | 12 | 2021 | 3719 | 0.750 |
Why?
|
| Humans | 180 | 2023 | 261506 | 0.740 |
Why?
|
| Fenretinide | 3 | 2009 | 96 | 0.730 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 661 | 0.720 |
Why?
|
| Antineoplastic Agents, Immunological | 9 | 2020 | 1249 | 0.720 |
Why?
|
| Oxazepines | 1 | 2019 | 2 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2014 | 2054 | 0.680 |
Why?
|
| Laryngeal Neoplasms | 5 | 2009 | 518 | 0.670 |
Why?
|
| Antibodies, Monoclonal | 4 | 2021 | 4367 | 0.670 |
Why?
|
| Piperazines | 6 | 2019 | 2101 | 0.670 |
Why?
|
| Aged | 87 | 2023 | 70117 | 0.660 |
Why?
|
| Imidazoles | 3 | 2019 | 999 | 0.640 |
Why?
|
| Neoplasm Staging | 30 | 2021 | 13658 | 0.640 |
Why?
|
| Middle Aged | 93 | 2021 | 86204 | 0.630 |
Why?
|
| Research Design | 6 | 2021 | 1544 | 0.620 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2012 | 1546 | 0.610 |
Why?
|
| Circulating Tumor DNA | 5 | 2021 | 235 | 0.600 |
Why?
|
| Male | 108 | 2023 | 123000 | 0.600 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 521 | 0.590 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 224 | 0.570 |
Why?
|
| Immunotherapy | 13 | 2022 | 3341 | 0.570 |
Why?
|
| Salvage Therapy | 4 | 2019 | 2054 | 0.560 |
Why?
|
| Carbazoles | 1 | 2016 | 87 | 0.560 |
Why?
|
| Female | 109 | 2023 | 141928 | 0.560 |
Why?
|
| Sirolimus | 6 | 2013 | 814 | 0.550 |
Why?
|
| Survival Rate | 24 | 2021 | 12221 | 0.530 |
Why?
|
| Chemoprevention | 7 | 2006 | 241 | 0.530 |
Why?
|
| Pyrimidines | 6 | 2020 | 3518 | 0.510 |
Why?
|
| Piperidines | 4 | 2016 | 1035 | 0.510 |
Why?
|
| Paclitaxel | 15 | 2019 | 1996 | 0.500 |
Why?
|
| beta Carotene | 3 | 2009 | 76 | 0.490 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 2283 | 0.490 |
Why?
|
| Adult | 72 | 2023 | 77950 | 0.490 |
Why?
|
| Patient Selection | 2 | 2021 | 2055 | 0.480 |
Why?
|
| Sulfones | 1 | 2015 | 143 | 0.480 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 216 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2023 | 10035 | 0.470 |
Why?
|
| Tongue Neoplasms | 2 | 2005 | 246 | 0.470 |
Why?
|
| Trypsin Inhibitor, Bowman-Birk Soybean | 1 | 2013 | 3 | 0.470 |
Why?
|
| Trypsin Inhibitors | 1 | 2013 | 18 | 0.460 |
Why?
|
| Retinoids | 6 | 2006 | 164 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2022 | 3251 | 0.460 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2020 | 406 | 0.450 |
Why?
|
| B7-H1 Antigen | 8 | 2023 | 1022 | 0.450 |
Why?
|
| Aged, 80 and over | 37 | 2021 | 29902 | 0.440 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 74 | 0.430 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 94 | 0.430 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2018 | 388 | 0.420 |
Why?
|
| Antimitotic Agents | 1 | 2011 | 8 | 0.420 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3230 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2020 | 419 | 0.410 |
Why?
|
| Treatment Outcome | 43 | 2021 | 32848 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 2594 | 0.370 |
Why?
|
| Platinum | 4 | 2020 | 138 | 0.370 |
Why?
|
| Cyclin D1 | 3 | 2009 | 576 | 0.370 |
Why?
|
| Tea | 1 | 2009 | 43 | 0.360 |
Why?
|
| Disease Progression | 12 | 2023 | 6682 | 0.350 |
Why?
|
| Cisplatin | 13 | 2020 | 2432 | 0.350 |
Why?
|
| Prognosis | 25 | 2023 | 21713 | 0.350 |
Why?
|
| Vitamin A | 2 | 2009 | 94 | 0.350 |
Why?
|
| Mitosis | 1 | 2011 | 615 | 0.340 |
Why?
|
| Everolimus | 6 | 2015 | 415 | 0.340 |
Why?
|
| Alkyl and Aryl Transferases | 3 | 2005 | 87 | 0.340 |
Why?
|
| Phytotherapy | 1 | 2009 | 110 | 0.340 |
Why?
|
| Laryngeal Diseases | 1 | 2009 | 49 | 0.330 |
Why?
|
| Paranasal Sinus Neoplasms | 2 | 2003 | 285 | 0.330 |
Why?
|
| Quinazolines | 7 | 2018 | 923 | 0.330 |
Why?
|
| Genomics | 8 | 2023 | 2738 | 0.320 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 14889 | 0.310 |
Why?
|
| Vitamins | 1 | 2008 | 157 | 0.310 |
Why?
|
| Pyrazoles | 4 | 2020 | 1471 | 0.310 |
Why?
|
| Plant Extracts | 1 | 2009 | 215 | 0.310 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2015 | 1823 | 0.300 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 5159 | 0.300 |
Why?
|
| Cohort Studies | 11 | 2021 | 9244 | 0.300 |
Why?
|
| Genetic Markers | 6 | 2018 | 974 | 0.300 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 200 | 0.300 |
Why?
|
| Neoplasms | 11 | 2021 | 15193 | 0.290 |
Why?
|
| Adenocarcinoma | 6 | 2016 | 7789 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 521 | 0.290 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 10001 | 0.280 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2020 | 1048 | 0.280 |
Why?
|
| Thiazoles | 1 | 2010 | 726 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2010 | 371 | 0.280 |
Why?
|
| Point Mutation | 4 | 2018 | 769 | 0.270 |
Why?
|
| Signal Transduction | 15 | 2018 | 11965 | 0.260 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2005 | 153 | 0.260 |
Why?
|
| Cell Cycle Proteins | 3 | 2019 | 2045 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2015 | 4938 | 0.250 |
Why?
|
| Survival Analysis | 14 | 2020 | 9180 | 0.240 |
Why?
|
| Benzodiazepines | 1 | 2005 | 170 | 0.240 |
Why?
|
| Genes, p53 | 3 | 2003 | 1090 | 0.230 |
Why?
|
| Tumor Burden | 6 | 2021 | 1987 | 0.230 |
Why?
|
| Neoplasm Metastasis | 6 | 2019 | 5112 | 0.230 |
Why?
|
| Interferon-alpha | 6 | 2009 | 889 | 0.230 |
Why?
|
| Immunohistochemistry | 10 | 2010 | 7548 | 0.230 |
Why?
|
| Protein Kinases | 2 | 2008 | 874 | 0.220 |
Why?
|
| Administration, Oral | 5 | 2016 | 1544 | 0.220 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 1375 | 0.220 |
Why?
|
| Papillomaviridae | 3 | 2019 | 624 | 0.220 |
Why?
|
| Pyridines | 6 | 2020 | 1244 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 6 | 2012 | 1290 | 0.220 |
Why?
|
| Diagnostic Imaging | 3 | 2017 | 1162 | 0.220 |
Why?
|
| Folic Acid Antagonists | 1 | 2022 | 45 | 0.210 |
Why?
|
| Bevacizumab | 4 | 2019 | 938 | 0.210 |
Why?
|
| Exons | 2 | 2018 | 1328 | 0.210 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2014 | 146 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2001 | 476 | 0.200 |
Why?
|
| Ipilimumab | 3 | 2023 | 710 | 0.200 |
Why?
|
| Vitamin E | 4 | 2001 | 136 | 0.200 |
Why?
|
| Lung | 7 | 2022 | 3151 | 0.200 |
Why?
|
| Cadherins | 1 | 2005 | 660 | 0.200 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2001 | 20 | 0.200 |
Why?
|
| Genes, ras | 2 | 2015 | 667 | 0.190 |
Why?
|
| Placebos | 4 | 2010 | 437 | 0.190 |
Why?
|
| Deglutition Disorders | 2 | 2016 | 447 | 0.190 |
Why?
|
| Membrane Glycoproteins | 3 | 2018 | 1073 | 0.190 |
Why?
|
| Prospective Studies | 14 | 2023 | 12873 | 0.180 |
Why?
|
| Genes, erbB-1 | 2 | 2018 | 101 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2018 | 3890 | 0.180 |
Why?
|
| Bites and Stings | 1 | 2020 | 44 | 0.180 |
Why?
|
| Cyclins | 1 | 2001 | 456 | 0.180 |
Why?
|
| Pneumonia | 2 | 2020 | 751 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2020 | 8873 | 0.180 |
Why?
|
| Radiation Injuries | 4 | 2016 | 1411 | 0.180 |
Why?
|
| Benzimidazoles | 2 | 2014 | 428 | 0.180 |
Why?
|
| Tissue Distribution | 2 | 2012 | 875 | 0.170 |
Why?
|
| Radiotherapy, Conformal | 2 | 2016 | 902 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 138 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 62 | 0.170 |
Why?
|
| Genes, Tumor Suppressor | 3 | 1998 | 1064 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2008 | 1823 | 0.170 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2018 | 973 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2015 | 1678 | 0.160 |
Why?
|
| Combined Modality Therapy | 10 | 2019 | 8865 | 0.160 |
Why?
|
| DNA, Neoplasm | 3 | 2018 | 1910 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 1998 | 181 | 0.160 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2018 | 141 | 0.160 |
Why?
|
| Retreatment | 1 | 2019 | 452 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 155 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 182 | 0.160 |
Why?
|
| Oncostatin M | 1 | 2017 | 23 | 0.150 |
Why?
|
| Time Factors | 11 | 2020 | 12926 | 0.150 |
Why?
|
| Tumor Microenvironment | 5 | 2023 | 2864 | 0.150 |
Why?
|
| ras Proteins | 3 | 2015 | 770 | 0.140 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.140 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 121 | 0.140 |
Why?
|
| Interleukin-2 | 1 | 2020 | 842 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2020 | 2291 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 615 | 0.140 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 483 | 0.140 |
Why?
|
| Cetuximab | 3 | 2019 | 472 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2019 | 546 | 0.140 |
Why?
|
| Retrospective Studies | 14 | 2022 | 37905 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 137 | 0.140 |
Why?
|
| Loss of Heterozygosity | 5 | 2016 | 602 | 0.140 |
Why?
|
| Binding Sites | 2 | 2018 | 2171 | 0.140 |
Why?
|
| Benzamides | 2 | 2019 | 1832 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2019 | 1756 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2016 | 409 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 702 | 0.130 |
Why?
|
| Diarrhea | 2 | 2016 | 686 | 0.130 |
Why?
|
| Fatigue | 4 | 2018 | 1239 | 0.130 |
Why?
|
| Taxoids | 7 | 2013 | 967 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 178 | 0.130 |
Why?
|
| Carcinoma | 2 | 2004 | 2578 | 0.130 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 80 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 332 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 2488 | 0.130 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 160 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2017 | 1248 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 962 | 0.130 |
Why?
|
| Mouth Mucosa | 3 | 2023 | 216 | 0.130 |
Why?
|
| Cell Line, Tumor | 11 | 2018 | 14551 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 5 | 2008 | 3203 | 0.120 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 750 | 0.120 |
Why?
|
| Pneumonectomy | 1 | 2020 | 831 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 571 | 0.120 |
Why?
|
| Drug Eruptions | 1 | 2016 | 256 | 0.120 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2016 | 199 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 1331 | 0.120 |
Why?
|
| Cytokines | 3 | 2017 | 2809 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2002 | 290 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 604 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2016 | 324 | 0.110 |
Why?
|
| Resorcinols | 1 | 2013 | 27 | 0.110 |
Why?
|
| Stomatitis | 2 | 2009 | 183 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2006 | 2359 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2015 | 2669 | 0.110 |
Why?
|
| Chromosome Deletion | 1 | 1998 | 1005 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 1382 | 0.110 |
Why?
|
| Young Adult | 10 | 2020 | 21445 | 0.110 |
Why?
|
| Genotype | 5 | 2020 | 4109 | 0.110 |
Why?
|
| Ifosfamide | 5 | 2009 | 344 | 0.110 |
Why?
|
| Isoxazoles | 1 | 2013 | 81 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 97 | 0.110 |
Why?
|
| RNA, Messenger | 4 | 2018 | 6150 | 0.110 |
Why?
|
| Hyperplasia | 3 | 2009 | 557 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2016 | 1105 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 1538 | 0.110 |
Why?
|
| Radiation-Protective Agents | 2 | 2004 | 128 | 0.110 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2005 | 323 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2013 | 2292 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 86 | 0.100 |
Why?
|
| Melanoma | 2 | 2020 | 5317 | 0.100 |
Why?
|
| Gene Amplification | 3 | 2019 | 731 | 0.100 |
Why?
|
| Inflammation | 4 | 2016 | 2522 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 3639 | 0.100 |
Why?
|
| Transcriptome | 2 | 2018 | 1859 | 0.100 |
Why?
|
| Trans-Activators | 3 | 2009 | 1555 | 0.100 |
Why?
|
| Gastrostomy | 1 | 2013 | 180 | 0.100 |
Why?
|
| Diterpenes | 2 | 2009 | 111 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 755 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 3821 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2005 | 852 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 848 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 1283 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2016 | 1152 | 0.100 |
Why?
|
| alpha-Tocopherol | 2 | 2009 | 78 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2013 | 2231 | 0.100 |
Why?
|
| Farnesyltranstransferase | 3 | 2005 | 122 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2011 | 829 | 0.090 |
Why?
|
| Camptothecin | 2 | 2003 | 517 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 2 | 2003 | 408 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 1121 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1423 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 980 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 2341 | 0.090 |
Why?
|
| Chromosome Aberrations | 4 | 2002 | 1960 | 0.090 |
Why?
|
| Nausea | 2 | 2018 | 525 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2013 | 1546 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 1533 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 106 | 0.090 |
Why?
|
| Tonsillar Neoplasms | 1 | 2010 | 80 | 0.090 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 4988 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 1866 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 4892 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2021 | 2803 | 0.080 |
Why?
|
| Gene Expression | 3 | 2016 | 3570 | 0.080 |
Why?
|
| Biopsy | 3 | 2018 | 3443 | 0.080 |
Why?
|
| Risk Factors | 9 | 2018 | 17523 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 363 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 1997 | 2022 | 0.080 |
Why?
|
| Etoposide | 4 | 2004 | 870 | 0.080 |
Why?
|
| Mice, Nude | 5 | 2018 | 4307 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 2518 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 3101 | 0.080 |
Why?
|
| Celecoxib | 1 | 2008 | 200 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 1879 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 3 | 2013 | 4975 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 3981 | 0.080 |
Why?
|
| Phenotype | 6 | 2020 | 6295 | 0.080 |
Why?
|
| Fluorouracil | 4 | 2019 | 1944 | 0.070 |
Why?
|
| Drug Synergism | 4 | 2018 | 1313 | 0.070 |
Why?
|
| Mouthwashes | 2 | 2004 | 41 | 0.070 |
Why?
|
| Dasatinib | 1 | 2010 | 862 | 0.070 |
Why?
|
| Thrombocytopenia | 2 | 2009 | 846 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2086 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 6207 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2005 | 700 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2023 | 992 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 3022 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 524 | 0.070 |
Why?
|
| Dyspnea | 1 | 2009 | 416 | 0.070 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 3472 | 0.070 |
Why?
|
| Animals | 11 | 2018 | 59536 | 0.070 |
Why?
|
| Probability | 2 | 2010 | 866 | 0.070 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2007 | 117 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 669 | 0.070 |
Why?
|
| Anemia | 2 | 2009 | 689 | 0.070 |
Why?
|
| Mice | 9 | 2018 | 34495 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 231 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 442 | 0.060 |
Why?
|
| Radiation Pneumonitis | 2 | 2004 | 301 | 0.060 |
Why?
|
| Microsatellite Repeats | 3 | 2001 | 575 | 0.060 |
Why?
|
| Apoptosis | 6 | 2023 | 7591 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 68 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2016 | 6869 | 0.060 |
Why?
|
| Ketorolac | 1 | 2004 | 20 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 287 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2002 | 311 | 0.060 |
Why?
|
| Eye Enucleation | 1 | 2003 | 91 | 0.060 |
Why?
|
| Neutropenia | 2 | 2005 | 968 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 171 | 0.060 |
Why?
|
| Adenoviridae | 3 | 2005 | 1459 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 1363 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 4849 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 5539 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 612 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7226 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 177 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 3 | 2002 | 1350 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2007 | 739 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 726 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4557 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2000 | 365 | 0.050 |
Why?
|
| Orbit | 1 | 2003 | 205 | 0.050 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 771 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 2104 | 0.050 |
Why?
|
| United States | 2 | 2016 | 15433 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2018 | 2450 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1764 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2002 | 58 | 0.050 |
Why?
|
| Cyclin D | 1 | 2001 | 37 | 0.050 |
Why?
|
| Cell Line | 3 | 2018 | 5114 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2003 | 2232 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 519 | 0.050 |
Why?
|
| Vinblastine | 1 | 2002 | 453 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 7551 | 0.050 |
Why?
|
| Adolescent | 4 | 2017 | 31252 | 0.050 |
Why?
|
| North America | 1 | 2021 | 314 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2003 | 304 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 243 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2016 | 2588 | 0.050 |
Why?
|
| Genes, p16 | 1 | 2000 | 125 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 5395 | 0.050 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 79 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2003 | 3552 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 995 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2015 | 1053 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 2074 | 0.050 |
Why?
|
| Smad4 Protein | 2 | 1998 | 196 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 641 | 0.040 |
Why?
|
| DNA-Binding Proteins | 3 | 2015 | 4821 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 2 | 2013 | 183 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 486 | 0.040 |
Why?
|
| DCC Receptor | 1 | 1998 | 14 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2018 | 78 | 0.040 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2018 | 41 | 0.040 |
Why?
|
| Cell Survival | 3 | 2011 | 3045 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 2002 | 487 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 124 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2020 | 370 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 673 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 327 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1323 | 0.040 |
Why?
|
| Receptors, Oncostatin M | 1 | 2017 | 8 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 61 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2002 | 4298 | 0.040 |
Why?
|
| Smad2 Protein | 1 | 1998 | 89 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 499 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2000 | 837 | 0.040 |
Why?
|
| Recurrence | 1 | 2005 | 4758 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2018 | 218 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 690 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 257 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1945 | 0.040 |
Why?
|
| Quinolones | 1 | 2018 | 160 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2018 | 869 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 4549 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2002 | 1353 | 0.040 |
Why?
|
| Multigene Family | 1 | 1998 | 425 | 0.040 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 202 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 479 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 1165 | 0.040 |
Why?
|
| Vomiting | 1 | 2018 | 354 | 0.040 |
Why?
|
| Parotid Neoplasms | 1 | 1997 | 148 | 0.030 |
Why?
|
| Leucovorin | 1 | 1997 | 332 | 0.030 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2017 | 107 | 0.030 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 2944 | 0.030 |
Why?
|
| Tretinoin | 1 | 2018 | 623 | 0.030 |
Why?
|
| B7 Antigens | 1 | 2016 | 84 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 1163 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 448 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 7222 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 577 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1996 | 176 | 0.030 |
Why?
|
| Quinolines | 1 | 2018 | 383 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2018 | 6100 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2015 | 245 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1471 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 978 | 0.030 |
Why?
|
| Child | 2 | 2017 | 29154 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 862 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2018 | 1144 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2021 | 1818 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2018 | 834 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 4971 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 190 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1997 | 1643 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| CpG Islands | 1 | 2015 | 633 | 0.030 |
Why?
|
| DNA | 1 | 2001 | 2693 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2015 | 4804 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2012 | 1694 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 799 | 0.030 |
Why?
|
| Proteomics | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 333 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 413 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 196 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 1335 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 80 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 435 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2012 | 126 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2013 | 3842 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1993 | 295 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 673 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.020 |
Why?
|
| Valine | 1 | 2012 | 176 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 169 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 153 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 134 | 0.020 |
Why?
|
| Cysteine | 1 | 2012 | 214 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1997 | 1039 | 0.020 |
Why?
|
| Teratogens | 1 | 2011 | 81 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 1993 | 315 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 1586 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 392 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 591 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 1872 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1993 | 321 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2019 | 1330 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 886 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4053 | 0.020 |
Why?
|
| Glycine | 1 | 2012 | 289 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 5047 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 4844 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 328 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 1129 | 0.020 |
Why?
|
| Tonsillectomy | 1 | 2010 | 102 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2005 | 3536 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2015 | 5270 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2008 | 116 | 0.020 |
Why?
|
| Capsules | 1 | 2007 | 53 | 0.020 |
Why?
|
| Proteins | 1 | 1996 | 1963 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2483 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 629 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 1665 | 0.020 |
Why?
|
| Anorexia | 1 | 2007 | 143 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.020 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2006 | 57 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 2314 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 2307 | 0.020 |
Why?
|
| Chromones | 1 | 2005 | 120 | 0.020 |
Why?
|
| Remission Induction | 2 | 2005 | 3569 | 0.020 |
Why?
|
| Glutamates | 1 | 2005 | 130 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2005 | 101 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 151 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 2084 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2004 | 38 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2139 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2006 | 587 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2018 | 2947 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2004 | 79 | 0.020 |
Why?
|
| Flavonoids | 1 | 2005 | 188 | 0.020 |
Why?
|
| Vinculin | 1 | 2004 | 18 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2005 | 471 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 301 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1547 | 0.010 |
Why?
|
| Leukopenia | 1 | 2004 | 151 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 329 | 0.010 |
Why?
|
| Morpholines | 1 | 2005 | 289 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2004 | 122 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2003 | 257 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 176 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 2370 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 502 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 592 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 661 | 0.010 |
Why?
|
| Smoking | 2 | 2004 | 2440 | 0.010 |
Why?
|
| Mesna | 1 | 2002 | 65 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2004 | 267 | 0.010 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2002 | 1 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 423 | 0.010 |
Why?
|
| Keratosis | 1 | 2002 | 39 | 0.010 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2002 | 84 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1993 | 1797 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1037 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 980 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 769 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2004 | 478 | 0.010 |
Why?
|
| Esophagitis | 1 | 2002 | 202 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 5377 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2003 | 749 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 986 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 716 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 2315 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 358 | 0.010 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 1998 | 22 | 0.010 |
Why?
|
| Mouth | 1 | 2000 | 122 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2003 | 649 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 3033 | 0.010 |
Why?
|
| Colorectal Neoplasms | 2 | 2006 | 3578 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 1954 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 1509 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4320 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 5673 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 551 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 144 | 0.010 |
Why?
|
| Texas | 1 | 2007 | 6311 | 0.010 |
Why?
|
| Sjogren's Syndrome | 1 | 1997 | 102 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 2002 | 569 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 2466 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 1299 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1824 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2003 | 1616 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 1399 | 0.010 |
Why?
|
| Life Tables | 1 | 1993 | 120 | 0.010 |
Why?
|
| Heterozygote | 1 | 1996 | 1020 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 875 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 1993 | 204 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1993 | 242 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2006 | 15694 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 4917 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 6089 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 2195 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1993 | 500 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1993 | 589 | 0.000 |
Why?
|